AL-ADTRAN
5.12.2023 14:01:36 CET | Business Wire | Press release
Adtran today celebrated adding over 300 new Mosaic One customers in under 18 months. The rapid adoption of Adtran’s cloud-based software-as-a-service (SaaS) platform highlights its ability to address the demands of modern broadband networks. Mosaic One optimizes network operations by utilizing advanced AI-driven algorithms to anticipate and resolve issues before they impact performance. Its three dedicated portals - Care, Operate and Promote – enable service providers to manage complex deployments, reduce costs and deliver superior services to their subscribers. What’s more, Mosaic One is vendor- and technology-neutral, providing an all-encompassing monitoring solution for FTTH, DOCSIS, DSL and fixed wireless networks across multiple vendors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205627594/en/
Adtran’s Mosaic One helps service providers maximize the value of their fiber networks. (Photo: Business Wire)
“DFN’s partnership with Adtran and Mosaic One delivers real-time data and insights for our network and customer service teams, allowing us to care for our customers and fiber network proactively and efficiently,” said Todd Way, CEO of DFN. “The Mosaic Marketing Center has also been a considerable time and cost saver for DFN. Our marketing manager can quickly execute and customize community-centered campaigns with the click of a few buttons. Mosaic One positively impacts our operations, our employees and our customers.”
Mosaic One is a vendor- and technology-agnostic solution designed to adapt to the evolving needs of both service providers and end-users. With its predictive insights, real-time monitoring and intuitive user interface, it provides new opportunities and alleviates the workload for support teams, network engineers and marketers. It’s also recently been enhanced with several new features and capabilities. These include Intellifi®, Adtran’s cloud-managed Wi-Fi solution. This provides service providers with unprecedented control over the home Wi-Fi experience, maximizing customer satisfaction, loyalty and spend.
Additionally, the newly introduced Mosaic Marketing Center is a comprehensive marketing platform, offering professionally produced promotional materials, including videos, animated explainers and local stock photography to amplify campaigns. It features an instant customization tool, enabling swift branding and deployment of content, ensuring service providers can quickly tailor and launch their marketing initiatives. Also integrated into the platform is the Fiber Gaming Network, a fully managed turnkey solution for esports management, presenting fresh avenues for revenue growth.
“In less than 18 months, Mosaic One has hit a huge milestone. We often talk about how it empowers service providers to maximize the value of fiber networks. But Mosaic One’s success is also due to the fact that it gives customers what they need — a service with no hidden fees and no additional charges post-deployment. Many of our new customers came to us drained by the intricate licensing and perplexing invoicing their prior vendors used. Instead, what you get with Mosaic One is one invoice, one service, one incredibly easy way to manage your entire network,” commented Robert Conger, GM of software platforms at Adtran. “Achieving 300 deployments in such a short period is impressive, but for Mosaic One, it’s just the beginning. With more service-enhancing and revenue-boosting features in the pipeline, we’ll help shape a new era of opportunity for service providers.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205627594/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
